Opioid Prescribing

In a recent study, researchers sought to determine potential reasons why physicians do not prescribe a certain pharmacotherapy to capacity for opioid addiction, or do not prescribe it at all. Findings were...

Following an FDA-issued withdrawal request, an abuse-deterrent opioid will be removed from the market.

The first immediate-release opioid to receive abuse-deterrent labeling was recently approved by the FDA.

A study examined the impact of trends in benzodiazepine and opioid use on hospital admissions and emergency room visits for opioid overdose.

The FDA is requiring boxed warnings for opioid analgesics and prescription opioid cough products related to combined use of certain opioids with benzodiazepines.

The FDA has released its finalized industry guidance for the development of abuse-deterring opioid drugs.